Human immunodeficiency virus type 1 (HIV-1) RNA end points in HIV clinical trials: Issues in interim monitoring and early stopping

Journal of Infectious Diseases

Volumn 177, Issue 3, 1998, Pages 761-765

  Zackin, R ^b   Marschner, I ^b   Andersen, J ^b   Cowles, M K ^b   De Gruttola, V ^b   Hammer, S ^b   Fischl, M ^b   Cotton, D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG RESEARCH; DRUG RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; BLOOD; METHODOLOGY; RECURRENT DISEASE; REPRODUCIBILITY; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS; HIV-1; HUMANS; RECURRENCE; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0032012755     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514244     Document Type: Review

References (17)

1. National Task Force on AIDS Drug Development. Recommendations of June 29 and 30. 1995.
2. Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: are we being misled? Ann Intern Med 1996;125:605-13.
3. Peto T. Surrogate markers in HIV disease. J Antimicrob Chemother 1996; 37(suppl B):161-70.
4. Fleming TR. Surrogate markers in AIDS and cancer trials. Stat Med 1994; 13:1423-35.
5. Ho DD. Viral counts count in HIV infection. Science 1996;272:1124-5.
6. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
7. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;217:1582-6.
8. Prentice RL. Surrogate end points in clinical trials: definitions and operational criteria. Stat Med 1989;8:431-40.
9. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate end points for chronic diseases. Stat Med 1992;11:167-78.
10. Lin DY, Fischl MA, Schoenfeld DA. Evaluating the role of CD4-lymphocyte counts as surrogate end points in human immunodeficiency virus clinical trials. Stat Med 1993;12:835-42.
11. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
12. NIH Panel to Define Principles of Therapy of HIV Infection. Report. 1997.
13. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nature Med 1996;2:625-9.
14. Hammer S, Crumpacker C, D'Aquila R, et al. Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trial Group Virology Committee. J Clin Microbiol 1993;31:2557-64.
15. + lymphocyte counts: an ACTG cross-protocol analysis [abstract 417]. In: 4th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Washington, DC). Alexandria, VA: Infectious Diseases Society of America, 1997.
16. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977;64:191-9.
17. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.